Re: Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

2020 ◽  
Vol 78 (1) ◽  
pp. 113-114 ◽  
Author(s):  
Gianluigi Califano ◽  
Evanguelos Xylinas
2020 ◽  
Vol 203 (4) ◽  
pp. 690-698 ◽  
Author(s):  
Vitaly Margulis ◽  
Maneka Puligandla ◽  
Edouard J. Trabulsi ◽  
Elizabeth R. Plimack ◽  
Elizabeth R. Kessler ◽  
...  

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS4585-TPS4585 ◽  
Author(s):  
Jean H. Hoffman-Censits ◽  
Vitaly Margulis ◽  
Noah M. Hahn ◽  
Edouard John Trabulsi ◽  
Allison Beaver ◽  
...  

2021 ◽  
Vol 39 (1) ◽  
pp. 74.e9-74.e16
Author(s):  
Joseph G. Cheaib ◽  
Lauren E. Claus ◽  
Hiten D. Patel ◽  
Max R. Kates ◽  
Andres Matoso ◽  
...  

2018 ◽  
Vol 104 (6) ◽  
pp. 451-458 ◽  
Author(s):  
Yu-Peng Wu ◽  
Yun-Zhi Lin ◽  
Min-Yi Lin ◽  
Ting-Ting Lin ◽  
Shao-Hao Chen ◽  
...  

Purpose: The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC). Methods: We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS. Results: In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016). Conclusions: Use of Su should be more selective for high-grade tumors, as it correlates with shorter BCRS. Tumors located in the ureter are associated with shorter BCRS than those located in the renal pelvis.


Urology ◽  
2019 ◽  
Vol 129 ◽  
pp. 146-152 ◽  
Author(s):  
Xiaosong Meng ◽  
Brian Chao ◽  
Varun Vijay ◽  
Hayley Silver ◽  
Ezra J. Margolin ◽  
...  

2017 ◽  
Vol 197 (3 Part 1) ◽  
pp. 580-589 ◽  
Author(s):  
Laura-Maria Krabbe ◽  
Okyaz Eminaga ◽  
Shahrokh F. Shariat ◽  
Ryan C. Hutchinson ◽  
Yair Lotan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document